

Javier Pemán

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8723446/publications.pdf>

Version: 2024-02-01

164
papers

7,709
citations

66250

44
h-index

78623

77
g-index

219
all docs

219
docs citations

219
times ranked

6980
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection of azole resistance in <i>Aspergillus fumigatus</i> complex isolates using MALDI-TOF mass spectrometry. <i>Clinical Microbiology and Infection</i> , 2022, 28, 260-266.	2.8	10
2	Novel Chromogenic Medium CHROMagar™ Candida Plus for Detection of <i>Candida auris</i> and Other <i>Candida</i> Species from Surveillance and Environmental Samples: A Multicenter Study. <i>Journal of Fungi</i> (Basel, Switzerland), 2022, 8, 281.	1.5	14
3	Host-pathogen interactions upon <i>Candida auris</i> infection: fungal behaviour and immune response in <i>Galleria mellonella</i> . <i>Emerging Microbes and Infections</i> , 2022, 11, 136-146.	3.0	11
4	In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of <i>Candida</i> : A European Study. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, .	1.8	15
5	Antifungal Resistance among Less Prevalent <i>Candida</i> Non- <i>albicans</i> and Other Yeasts versus Established and under Development Agents: A Literature Review. <i>Journal of Fungi</i> (Basel, Switzerland), 2021, 7, 24.	1.5	11
6	Oligonucleotide-capped nanoporous anodic alumina biosensor as diagnostic tool for rapid and accurate detection of <i>Candida auris</i> in clinical samples. <i>Emerging Microbes and Infections</i> , 2021, 10, 407-415.	3.0	15
7	<i>Candida auris</i> : A New, Threatening Yeast. , 2021, , 544-555.		0
8	Lack of evidence for infectious SARS-CoV-2 in feces and sewage. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 2665-2667.	1.3	26
9	Azole resistance survey on clinical <i>Aspergillus fumigatus</i> isolates in Spain. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1170.e1-1170.e7.	2.8	34
10	Characterization of the Differential Pathogenicity of <i>Candida auris</i> in a <i>Galleria mellonella</i> Infection Model. <i>Microbiology Spectrum</i> , 2021, 9, e0001321.	1.2	27
11	Filamentous fungi in the airway of patients with cystic fibrosis: Just spectators?. <i>Revista Iberoamericana De Micología</i> , 2021, 38, 168-174.	0.4	2
12	Microbiological assessment of arterial allografts processed in a tissue bank. <i>Cell and Tissue Banking</i> , 2021, 22, 539-549.	0.5	0
13	Lack of relationship between genotype and virulence in <i>Candida</i> species. <i>Revista Iberoamericana De Micología</i> , 2021, 38, 9-11.	0.4	0
14	Candidemia Diagnosis With T2 Nuclear Magnetic Resonance in a PICU: A New Approach. <i>Pediatric Critical Care Medicine</i> , 2021, 22, e109-e114.	0.2	5
15	In Vitro Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Amphotericin B against <i>Candida auris</i> . <i>Pharmaceutics</i> , 2021, 13, 1767.	2.0	5
16	Invasive scedosporiosis in lung transplant recipients: A nine-year retrospective study in a tertiary care hospital. <i>Revista Iberoamericana De Micología</i> , 2021, 38, 184-187.	0.4	4
17	What Do We Know about <i>Candida auris</i> ? State of the Art, Knowledge Gaps, and Future Directions. <i>Microorganisms</i> , 2021, 9, 2177.	1.6	28
18	An evidence-based bundle improves the quality of care and outcomes of patients with candidaemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 730-737.	1.3	17

#	ARTICLE	IF	CITATIONS
19	Fungal co-infection in COVID-19 patients: Should we be concerned?. <i>Revista Iberoamericana De Micología</i> , 2020, 37, 41-46.	0.4	113
20	Recent changes in candidemia trends in a tertiary hospital (2011–2018). <i>Revista Iberoamericana De Micología</i> , 2020, 37, 87-93.	0.4	3
21	Triplex Hybridization-Based Nanosystem for the Rapid Screening of <i>Pneumocystis Pneumonia</i> in Clinical Samples. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 292.	1.5	6
22	Contamination of tissue allografts from a multiorgan–multitissue donor colonized by <i>Candida auris</i> . <i>Transplant Infectious Disease</i> , 2020, 23, e13535.	0.7	1
23	Genotyping Reveals High Clonal Diversity and Widespread Genotypes of <i>Candida</i> Causing Candidemia at Distant Geographical Areas. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 166.	1.8	20
24	Candidemia <i>Candida albicans</i> clusters have higher tendency to form biofilms than singleton genotypes. <i>Medical Mycology</i> , 2020, 58, 887-895.	0.3	2
25	Fungal infections following treatment with monoclonal antibodies and other immunomodulatory therapies. <i>Revista Iberoamericana De Micología</i> , 2020, 37, 5-16.	0.4	14
26	Utility of two PCR–RFLP–based techniques for identification of <i>Candida parapsilosis</i> complex blood isolates. <i>Mycoses</i> , 2020, 63, 461-470.	1.8	3
27	Factors associated with the development of septic shock in patients with candidemia: a post hoc analysis from two prospective cohorts. <i>Critical Care</i> , 2020, 24, 117.	2.5	19
28	Aptamer-Capped nanoporous anodic alumina for <i>Staphylococcus aureus</i> detection. <i>Sensors and Actuators B: Chemical</i> , 2020, 320, 128281.	4.0	31
29	Executive summary of clinical practice guideline for the management of invasive diseases caused by <i>Aspergillus</i> : 2018 Update by the GEMICOMED-SEIMC/REIPI. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 535-541.	0.3	46
30	Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis. <i>Annals of Hematology</i> , 2019, 98, 2081-2088.	0.8	16
31	Identification of Off-Patent Compounds That Present Antifungal Activity Against the Emerging Fungal Pathogen <i>Candida auris</i> . <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 83.	1.8	57
32	Selective and Sensitive Probe Based in Oligonucleotide-Capped Nanoporous Alumina for the Rapid Screening of Infection Produced by <i>Candida albicans</i> . <i>ACS Sensors</i> , 2019, 4, 1291-1298.	4.0	38
33	Detection and treatment of <i>Candida auris</i> in an outbreak situation: risk factors for developing colonization and candidemia by this new species in critically ill patients. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 295-305.	2.0	49
34	Outbreak of <i>Candida auris</i> in Spain: A comparison of antifungal activity by three methods with published data. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 541-546.	1.1	35
35	Invasive fungal infection in critically ill patients: hurdles and next challenges. <i>Journal of Chemotherapy</i> , 2019, 31, 64-73.	0.7	10
36	Usefulness of guideline recommendations for prognosis in patients with candidemia. <i>Medical Mycology</i> , 2019, 57, 659-667.	0.3	24

#	ARTICLE	IF	CITATIONS
37	Validation of a multivariable prediction model for post-transplant invasive fungal disease in 465 adult allogeneic hematopoietic stem cell transplant recipients. <i>Mycoses</i> , 2019, 62, 418-427.	1.8	3
38	Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in <i>Candida</i> and <i>Aspergillus</i> Species for the Sensititre YeastOne Colorimetric Broth and Etest Agar Diffusion Methods. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	59
39	Time-kill assays of amphotericin B plus anidulafungin against <i>Candida tropicalis</i> biofilms formed on two different biomaterials. <i>International Journal of Artificial Organs</i> , 2018, 41, 23-27.	0.7	3
40	An outbreak due to <i>Candida auris</i> with prolonged colonisation and candidaemia in a tertiary care European hospital. <i>Mycoses</i> , 2018, 61, 498-505.	1.8	236
41	Guía práctica de tratamiento urgente de la microangiopatía trombótica. <i>Medicina Clínica</i> , 2018, 151, 123.e1-123.e9.	0.3	7
42	Developing collaborative works for faster progress on fungal respiratory infections in cystic fibrosis. <i>Medical Mycology</i> , 2018, 56, S42-S59.	0.3	27
43	<i>Scedosporium</i> and <i>Lomentospora</i> : an updated overview of underrated opportunists. <i>Medical Mycology</i> , 2018, 56, S102-S125.	0.3	186
44	Salvage therapy with topical posaconazole in lung transplant recipients with invasive <i>Scedosporium</i> infection. <i>American Journal of Transplantation</i> , 2018, 18, 504-509.	2.6	19
45	Mobilisation Mechanism of Pathogenicity Islands by Endogenous Phages in <i>Staphylococcus aureus</i> clinical strains. <i>Scientific Reports</i> , 2018, 8, 16742.	1.6	14
46	Candidemia from urinary tract source: the challenge of candiduria. <i>Hospital Practice (1995)</i> , 2018, 46, 243-245.	0.5	12
47	T2Candida® to guide antifungal and length of treatment of candidemia in a pediatric multivisceral transplant recipient. <i>Medical Mycology Case Reports</i> , 2018, 21, 66-68.	0.7	8
48	Molecular Identification and Susceptibility Testing of Molds Isolated in a Prospective Surveillance of Triazole Resistance in Spain (FILPOP2 Study). <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	33
49	Molecular identification of <i>Candida auris</i> by PCR amplification of species-specific GPI protein-encoding genes. <i>International Journal of Medical Microbiology</i> , 2018, 308, 812-818.	1.5	34
50	Nosocomial fungemia by <i>Candida auris</i> : First four reported cases in continental Europe. <i>Revista Iberoamericana De Micología</i> , 2017, 34, 23-27.	0.4	110
51	Echinocandins Compared to Fluconazole for Candidemia of a Urinary Tract Source: A Propensity Score Analysis. <i>Clinical Infectious Diseases</i> , 2017, 64, 1374-1379.	2.9	19
52	JAVEA consensus guidelines for the treatment of <i>Candida</i> peritonitis and other intra-abdominal fungal infections in non-neutropenic critically ill adult patients. <i>Revista Iberoamericana De Micología</i> , 2017, 34, 130-142.	0.4	12
53	Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia. <i>Clinical Microbiology and Infection</i> , 2017, 23, 49.e1-49.e8.	2.8	41
54	Activity of Amphotericin B and Anidulafungin Combined with Rifampicin, Clarithromycin, Ethylenediaminetetraacetic Acid, N-Acetylcysteine, and Farnesol against <i>Candida tropicalis</i> Biofilms. <i>Journal of Fungi (Basel, Switzerland)</i> , 2017, 3, 16.	1.5	15

#	ARTICLE	IF	CITATIONS
55	PARASITIC INFECTIONS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 8, 211-2035.	0.5	18
56	Candidemia in major burns patients. <i>Mycoses</i> , 2016, 59, 391-398.	1.8	13
57	Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score-derived analysis of a population-based, multicentre prospective cohort. <i>Clinical Microbiology and Infection</i> , 2016, 22, 733.e1-733.e8.	2.8	34
58	Multilocus microsatellite analysis of European and African <i>Candida glabrata</i> isolates. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2016, 35, 885-892.	1.3	10
59	Bacterial and fungal contamination risks in human oocyte and embryo cryopreservation: open versus closed vitrification systems. <i>Fertility and Sterility</i> , 2016, 106, 127-132.	0.5	25
60	EPICO 3.0. Recommendations on invasive candidiasis in patients with complicated intra-abdominal infection and surgical patients with ICU extended stay. <i>Revista Iberoamericana De Micología</i> , 2016, 33, 196-205.	0.4	13
61	Risk factors, clinical presentation and prognosis of mixed candidaemia: a population-based surveillance in Spain. <i>Mycoses</i> , 2016, 59, 636-643.	1.8	8
62	Breakthrough candidaemia in the era of broad-spectrum antifungal therapies. <i>Clinical Microbiology and Infection</i> , 2016, 22, 181-188.	2.8	44
63	<i>Candida tropicalis</i> bloodstream infection: Incidence, risk factors and outcome in a population-based surveillance. <i>Journal of Infection</i> , 2015, 71, 385-394.	1.7	39
64	Epidemiology and outcome of candidaemia in patients with oncological and haematological malignancies: results from a population-based surveillance in Spain. <i>Clinical Microbiology and Infection</i> , 2015, 21, 491.e1-491.e10.	2.8	57
65	A simple prediction score for estimating the risk of candidaemia caused by fluconazole non-susceptible strains. <i>Clinical Microbiology and Infection</i> , 2015, 21, 684.e1-684.e9.	2.8	19
66	Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis. <i>Bone Marrow Transplantation</i> , 2015, 50, 1465-1472.	1.3	33
67	Multicenter Study of Epidemiological Cutoff Values and Detection of Resistance in <i>Candida</i> spp. to Anidulafungin, Caspofungin, and Micafungin Using the Sensititre YeastOne Colorimetric Method. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6725-6732.	1.4	57
68	Invasive <i>Candida</i> infections in surgical patients in intensive care units: a prospective, multicentre survey initiated by the European Confederation of Medical Mycology (ECMM) (2006-2008). <i>Clinical Microbiology and Infection</i> , 2015, 21, 87.e1-87.e10.	2.8	96
69	State of the Art in the Laboratory Methods for the Diagnosis of Invasive Fungal Diseases. , 2014, , 281-297.		1
70	Impact of Therapeutic Strategies on the Prognosis of Candidemia in the ICU*. <i>Critical Care Medicine</i> , 2014, 42, 1423-1432.	0.4	127
71	Molecular Identification and Antifungal Susceptibility of Yeast Isolates Causing Fungemia Collected in a Population-Based Study in Spain in 2010 and 2011. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1529-1537.	1.4	112
72	Epidemiology and predictive factors for early and late mortality in <i>Candida</i> bloodstream infections: a population-based surveillance in Spain. <i>Clinical Microbiology and Infection</i> , 2014, 20, O245-O254.	2.8	241

#	ARTICLE	IF	CITATIONS
73	Initial Use of Echinocandins Does Not Negatively Influence Outcome in <i>Candida parapsilosis</i> Bloodstream Infection: A Propensity Score Analysis. <i>Clinical Infectious Diseases</i> , 2014, 58, 1413-1421.	2.9	104
74	Rapid and specific detection of section <i>Fumigati</i> and <i>Aspergillus fumigatus</i> in human samples using a new multiplex real-time PCR. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 80, 111-118.	0.8	11
75	Clinical validation of a multiplex real-time PCR assay for detection of invasive candidiasis in intensive care unit patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3134-3141.	1.3	51
76	The <i>aspHS</i> gene as a new target for detecting <i>Aspergillus fumigatus</i> during infections by quantitative real-time PCR. <i>Medical Mycology</i> , 2013, 51, 545-554.	0.3	17
77	Epidemiological Cutoff Values for Fluconazole, Itraconazole, Posaconazole, and Voriconazole for Six <i>Candida</i> Species as Determined by the Colorimetric Sensititre YeastOne Method. <i>Journal of Clinical Microbiology</i> , 2013, 51, 2691-2695.	1.8	35
78	Examination of the in vitro fungicidal activity of echinocandins against <i>Candida lusitanae</i> by time-killing methods. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 864-868.	1.3	22
79	Population-Based Survey of Filamentous Fungi and Antifungal Resistance in Spain (FILPOP Study). <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3380-3387.	1.4	206
80	Effect of Statin Use on Outcomes of Adults with Candidemia. <i>PLoS ONE</i> , 2013, 8, e77317.	1.1	15
81	Combined use of nonculture-based lab techniques in the diagnosis and management of critically ill patients with invasive fungal infections. <i>Expert Review of Anti-Infective Therapy</i> , 2012, 10, 1321-1330.	2.0	17
82	Wild-Type MIC Distributions and Epidemiological Cutoff Values for Amphotericin B, Flucytosine, and Itraconazole and <i>Candida</i> spp. as Determined by CLSI Broth Microdilution. <i>Journal of Clinical Microbiology</i> , 2012, 50, 2040-2046.	1.8	128
83	Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1181-1187.	1.3	136
84	Comparison of Three Statistical Methods for Establishing Tentative Wild-Type Population and Epidemiological Cutoff Values for Echinocandins, Amphotericin B, Flucytosine, and Six <i>Candida</i> Species as Determined by the Colorimetric Sensititre YeastOne Method. <i>Journal of Clinical Microbiology</i> , 2012, 50, 3921-3926.	1.8	50
85	Voriconazole inhibits biofilm formation in different species of the genus <i>Candida</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2418-2423.	1.3	26
86	Antifungal Activity against <i>Candida</i> Biofilms. <i>International Journal of Artificial Organs</i> , 2012, 35, 780-791.	0.7	26
87	Epidemiology and echinocandin susceptibility of <i>Candida parapsilosis</i> sensu lato species isolated from bloodstream infections at a Spanish university hospital. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2739-2748.	1.3	40
88	Evaluation of disk diffusion method compared to broth microdilution for antifungal susceptibility testing of 3 echinocandins against <i>Aspergillus</i> spp.. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 73, 53-56.	0.8	14
89	Antifungal Susceptibility Testing of Filamentous Fungi. <i>Current Fungal Infection Reports</i> , 2012, 6, 41-50.	0.9	16
90	Comparison of micafungin MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) and Etest for <i>Candida</i> spp. isolates. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 70, 54-59.	0.8	6

#	ARTICLE	IF	CITATIONS
91	Control measures for <i>Acinetobacter baumannii</i> : a survey of Spanish hospitals. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2011, 29, 36-38.	0.3	8
92	Differentiation of <i>Candida parapsilosis</i> , <i>C. orthopsilosis</i> , and <i>C. metapsilosis</i> by specific PCR amplification of the RPSO intron. <i>International Journal of Medical Microbiology</i> , 2011, 301, 531-535.	1.5	15
93	Update on invasive mycoses by filamentous fungi in critically ill patients. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2011, 29, 36-41.	0.3	4
94	Clinical factors associated with a <i>Candida albicans</i> Germ Tube Antibody positive test in Intensive Care Unit patients. <i>BMC Infectious Diseases</i> , 2011, 11, 60.	1.3	41
95	Epidemiology and Antifungal Susceptibility of Bloodstream Fungal Isolates in Pediatric Patients: a Spanish Multicenter Prospective Survey. <i>Journal of Clinical Microbiology</i> , 2011, 49, 4158-4163.	1.8	60
96	Prospective Multicenter Study of the Epidemiology, Molecular Identification, and Antifungal Susceptibility of <i>Candida parapsilosis</i> , <i>Candida orthopsilosis</i> , and <i>Candida metapsilosis</i> Isolated from Patients with Candidemia. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5590-5596.	1.4	126
97	Assessment of Two New Molecular Methods for Identification of <i>Candida parapsilosis</i> Sensu Lato Species. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3257-3261.	1.8	30
98	Increased Mortality in Young Candidemia Patients Associated with Presence of a <i>Candida albicans</i> General-Purpose Genotype. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3250-3256.	1.8	28
99	Emerging Resistance to Azoles and Echinocandins: Clinical Relevance and Laboratory Detection. <i>Current Fungal Infection Reports</i> , 2010, 4, 186-195.	0.9	5
100	Current diagnostic approaches to invasive candidiasis in critical care settings. <i>Mycoses</i> , 2010, 53, 424-433.	1.8	49
101	Comparison of Anidulafungin MICs Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Method (M27-A3 Document) and Etest for <i>Candida</i> Species Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1347-1350.	1.4	16
102	Evaluation of the Etest method for susceptibility testing of <i>Aspergillus</i> spp. and <i>Fusarium</i> spp. to three echinocandins. <i>Medical Mycology</i> , 2010, 48, 858-861.	0.3	32
103	<i>In Vitro</i> Fungicidal Activities of Echinocandins against <i>Candida metapsilosis</i> , <i>C. orthopsilosis</i> , and <i>C. parapsilosis</i> Evaluated by Time-Kill Studies. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2194-2197.	1.4	62
104	Successful Topical Application of Caspofungin in the Treatment of Fungal Keratitis Refractory to Voriconazole. <i>JAMA Ophthalmology</i> , 2010, 128, 941.	2.6	27
105	Nationwide Sentinel Surveillance of Bloodstream <i>Candida</i> Infections in 40 Tertiary Care Hospitals in Spain. <i>Journal of Clinical Microbiology</i> , 2010, 48, 4200-4206.	1.8	64
106	Role of De-Escalation and Combination Therapy Strategies in the Management of Invasive Fungal Infection: A Multidisciplinary Point of View. , 2010, , 241-272.		0
107	Pharmacotherapy of <i>Candida</i> Infections with Echinocandins. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2311.	0.1	4
108	Kinetic Patterns of <i>Candida albicans</i> Germ Tube Antibody in Critically Ill Patients: Influence on Mortality. <i>Vaccine Journal</i> , 2009, 16, 1527-1528.	3.2	26

#	ARTICLE	IF	CITATIONS
109	In Vitro Activities of Echinocandins against <i>Candida krusei</i> Determined by Three Methods: MIC and Minimal Fungicidal Concentration Measurements and Time-Kill Studies. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3108-3111.	1.4	34
110	Uneven Distribution of Mating Types among Genotypes of <i>Candida glabrata</i> Isolates from Clinical Samples. <i>Eukaryotic Cell</i> , 2009, 8, 287-295.	3.4	54
111	Updates in antifungal susceptibility testing of filamentous fungi. <i>Current Fungal Infection Reports</i> , 2009, 3, 133-141.	0.9	17
112	Identification of pathogenic yeast species by polymerase chain reaction amplification of the RPS0 gene intron fragment. <i>Journal of Applied Microbiology</i> , 2009, 108, 1917-27.	1.4	15
113	Clinical significance of the detection of <i>Candida albicans</i> germ tube-specific antibodies in critically ill patients. <i>Clinical Microbiology and Infection</i> , 2009, 15, 592-595.	2.8	36
114	Antifungal drug resistance mechanisms. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 453-460.	2.0	99
115	Comparison of 24-Hour and 48-Hour Voriconazole MICs as Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Method (M27-A3 Document) in Three Laboratories: Results Obtained with 2,162 Clinical Isolates of <i>Candida</i> spp. and Other Yeasts. <i>Journal of Clinical Microbiology</i> , 2009, 47, 2766-2771.	1.8	38
116	Trends in antifungal susceptibility testing using CLSI reference and commercial methods. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 107-119.	2.0	95
117	Unexpected Postmortem Diagnosis of <i>Acanthamoeba</i> Meningoencephalitis Following Allogeneic Peripheral Blood Stem Cell Transplantation. <i>American Journal of Transplantation</i> , 2008, 8, 1562-1566.	2.6	25
118	Fungemia due to <i>Candida guilliermondii</i> in a pediatric and adult population during a 12-year period. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 60, 109-112.	0.8	27
119	Comparison of posaconazole and voriconazole in vitro killing against <i>Candida krusei</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 62, 177-181.	0.8	12
120	Latest developments in fungal lung infection in solid organ transplantation (SOT). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2008, 26, 49-57.	0.3	1
121	Comparison of E-Test®, disk diffusion and a modified CLSI broth microdilution (M 38-A) method for in vitro testing of itraconazole, fluconazole and voriconazole against dermatophytes. <i>Medical Mycology</i> , 2008, 46, 119-123.	0.3	30
122	Activity of BAL 4815 against filamentous fungi. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 1083-1086.	1.3	23
123	Comparison of the Sensititre YeastOne® Colorimetric Antifungal Panel with the Modified Clinical and Laboratory Standards Institute Broth Microdilution (M38-A) Method for Antifungal Susceptibility Testing of Dermatophytes. <i>Chemotherapy</i> , 2008, 54, 427-430.	0.8	11
124	Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 1261-1280.	0.9	33
125	Comparison of disc diffusion assay with the CLSI reference method (M27-A2) for testing in vitro posaconazole activity against common and uncommon yeasts. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 135-138.	1.3	14
126	Update on invasive fungal infections: the last two years. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2007, 25, 19-27.	0.3	0

#	ARTICLE	IF	CITATIONS
127	Histoplasmosis diseminada con síndrome hemofagocítico en un paciente con sida: descripción de un caso y revisión de la literatura española. Revista Iberoamericana De Micología, 2007, 24, 312-316.	0.4	28
128	Candidaemia in Europe: epidemiology and resistance. International Journal of Antimicrobial Agents, 2006, 27, 359-366.	1.1	303
129	In vitro antifungal susceptibility testing of filamentous fungi with Sensititre Yeast One™. Mycoses, 2006, 49, 293-297.	1.8	32
130	Epidemiology of invasive fungal infections due to Aspergillus spp. and Zygomycetes. Clinical Microbiology and Infection, 2006, 12, 2-6.	2.8	70
131	Food and probiotic strains from the Saccharomyces cerevisiae species as a possible origin of human systemic infections. International Journal of Food Microbiology, 2006, 110, 286-290.	2.1	61
132	Infección fúngica invasora en el paciente crítico: diferentes opciones terapéuticas y una misma estrategia. Revista Iberoamericana De Micología, 2006, 23, 59-63.	0.4	19
133	Killing Kinetics of Caspofungin, Micafungin, and Amphotericin B against Candida guilliermondii. Antimicrobial Agents and Chemotherapy, 2006, 50, 2829-2832.	1.4	36
134	Evaluation of Disk Diffusion Method for Determining Posaconazole Susceptibility of Filamentous Fungi: Comparison with CLSI Broth Microdilution Method. Antimicrobial Agents and Chemotherapy, 2006, 50, 1108-1111.	1.4	36
135	Spondylodiscitis Caused by Candida krusei: Case Report and Susceptibility Patterns. Journal of Clinical Microbiology, 2006, 44, 1912-1914.	1.8	27
136	Voriconazole in the management of nosocomial invasive fungal infections. Therapeutics and Clinical Risk Management, 2006, 2, 129-157.	0.9	49
137	Aspergillus infections in lung transplant recipients: risk factors and outcome. Clinical Microbiology and Infection, 2005, 11, 359-365.	2.8	157
138	Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. European Journal of Clinical Microbiology and Infectious Diseases, 2005, 24, 23-30.	1.3	99
139	Synergistic Activities of Fluconazole and Voriconazole with Terbinafine against Four Candida Species Determined by Checkerboard, Time-Kill, and Etest Methods. Antimicrobial Agents and Chemotherapy, 2005, 49, 1593-1596.	1.4	57
140	Sensititre YeastOne Caspofungin Susceptibility Testing of Candida Clinical Isolates: Correlation with Results of NCCLS M27-A2 Multicenter Study. Antimicrobial Agents and Chemotherapy, 2005, 49, 1604-1607.	1.4	13
141	Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species. Journal of Clinical Microbiology, 2004, 42, 3475-3482.	1.8	174
142	Blastoschizomyces capitatus Infection in Patients with Leukemia: Report of 26 Cases. Clinical Infectious Diseases, 2004, 38, 335-341.	2.9	108
143	Routine Use of a Commercial Test, GLABRATA RTT, for Rapid Identification of Candida glabrata in Six Laboratories. Journal of Clinical Microbiology, 2004, 42, 4870-4872.	1.8	22
144	Patterns of Amphotericin B Killing Kinetics against Seven Candida Species. Antimicrobial Agents and Chemotherapy, 2004, 48, 2477-2482.	1.4	105

#	ARTICLE	IF	CITATIONS
145	Epidemiology of Candidaemia in Europe: Results of 28-Month European Confederation of Medical Mycology (ECMM) Hospital-Based Surveillance Study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2004, 23, 317-322.	1.3	441
146	The C-terminal antibody binding domain of <i>Candida albicans</i> p58 represents a protective epitope during candidiasis. <i>FEMS Microbiology Letters</i> , 2004, 232, 133-138.	0.7	30
147	Performance of Bactocard™ <i>Candida</i> compared with the germ tube test for the presumptive identification of <i>Candida albicans</i> . <i>Mycoses</i> , 2003, 46, 467-470.	1.8	10
148	Visceral leishmaniasis in lung transplantation. <i>Transplantation Proceedings</i> , 2003, 35, 2001-2003.	0.3	39
149	In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against <i>Aspergillus</i> spp. <i>Diagnostic Microbiology and Infectious Disease</i> , 2003, 45, 131-135.	0.8	85
150	Minimum fungicidal concentrations of amphotericin B for bloodstream <i>Candida</i> species. <i>Diagnostic Microbiology and Infectious Disease</i> , 2003, 45, 203-206.	0.8	117
151	Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of <i>Aspergillus</i> spp.. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 52, 365-370.	1.3	63
152	Actividad in vitro de voriconazol y otros tres antifúngicos frente a dermatofitos. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2003, 21, 484-487.	0.3	9
153	Comparison of in vitro Antifungal Activities of Amphotericin B Lipid Complex with Itraconazole against 708 Clinical Yeast Isolates and Opportunistic Moulds Determined by National Committee for Clinical Laboratory Standards Methods M27-A and M38-P. <i>Chemotherapy</i> , 2002, 48, 224-231.	0.8	8
154	Two Cases of Fungemia due to <i>Candida lusitanae</i> and a Literature Review. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2002, 21, 294-299.	1.3	23
155	Infectious complications in patients undergoing unrelated donor bone marrow transplantation: experience from a single institution. <i>Clinical Microbiology and Infection</i> , 2002, 8, 725-733.	2.8	29
156	Candidemia at a Tertiary-Care Hospital: Epidemiology, Treatment, Clinical Outcome and Risk Factors for Death. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2002, 21, 767-774.	1.3	211
157	Comparative in vitro Antifungal Activity of Amphotericin B Lipid Complex, Amphotericin B and Fluconazole. <i>Chemotherapy</i> , 2000, 46, 235-244.	0.8	33
158	In vitro Susceptibility of <i>Candida dubliniensis</i> to Current and New Antifungal Agents. <i>Chemotherapy</i> , 2000, 46, 395-401.	0.8	58
159	Human intestinal infection due to coccidia in Mozambique: two cases. <i>Acta Tropica</i> , 1999, 72, 25-29.	0.9	5
160	Killing of Gram-Negative Bacteria by Ciprofloxacin within both Healthy Human Neutrophils and Neutrophils with Inactivated O ₂ -Dependent Bactericidal Mechanisms. <i>Chemotherapy</i> , 1999, 45, 268-276.	0.8	13
161	Mechanisms of Action of Quinolones against Staphylococci and Relationship with Their in vitro Bactericidal Activity. <i>Chemotherapy</i> , 1999, 45, 175-182.	0.8	7
162	Intraphagocytic killing of Gram-positive bacteria by ciprofloxacin. <i>Journal of Antimicrobial Chemotherapy</i> , 1994, 34, 965-974.	1.3	20

#	ARTICLE	IF	CITATIONS
163	In-vitro postantibiotic effect of sparfloxacin and ciprofloxacin against <i>Pseudomonas aeruginosa</i> and <i>Enterococcus faecalis</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 1994, 34, 679-685.	1.3	13
164	Intraphagocytic bioactivity of lomefloxacin against <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 1993, 32, 279-284.	1.3	4